TiGenix rheumatoid arthritis Phase IIa study successfully passes last safety hurdle
TiGenix announced that upon review of the safety data of the first three patients of the third cohort of the company's Phase IIa clinical trial in rheumatoid arthritis (Cx611) it has received the go-ahead from the independent Safety Monitoring Board to recruit and dose the remaining patients of this cohort. The Phase IIa trial is based on a three-step dose-finding protocol, where each step starts with a safety review of the first three patients after 40 days of dosing.
"With this last step, we have reached a key milestone in our Phase IIa trial in RA," said Eduardo Bravo, CEO of TiGenix. "The fact that the highest dose has proven safe is of major importance. In RA it ensures that we will not be held back by any dose-limiting factors and we will be able to move forward with the optimal treatment dose. But of almost equal importance is that, if required, we can expand the dosing range in other indications that we are exploring as well. With 6 months of follow-up, the current RA trial in 53 patients is expected to report meaningful results in H1 2013."
Other news from the department research and development
